Back to search

Peptide record

TPDB08901

Antibacterial Antifungal Hemolysis Toxicity standard
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB08901
Antibacterial Antifungal Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 DRAMP Peptipedia Antifungipept CAFPdb dbAMP HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 18-aa standard-residue multi-activity (Antibacterial, Antifungal, Hemolysis, and other sources) peptide sequence curated from AntiBP3, DRAMP, Peptipedia, and other sources, with an available 3D structural model.
Sequence
GLLGKLLKIAAKVGSNLL
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C84H154N22O21
RDCEQHMFPTWY
L
1808.28
10.84
3
0
10
+3
-1.01
0.994
178.89
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
2
Residue Composition
number
2
A
0
R
1
N
0
D
0
C
0
E
0
Q
3
G
0
H
1
I
6
L
3
K
0
M
0
F
0
P
1
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 2 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 3 H: 0 I: 1 L: 6 K: 3 M: 0 F: 0 P: 0 S: 1 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
18 reviewed residue count
C84H154N22O21 sequence-only estimate (linear, free termini)
1808.28 sequence-only estimate (linear, free termini)
10.84 sequence-only estimate (linear, free termini)
+3 sequence-only estimate (linear, free termini)
-1.01 sequence-only estimate (linear, free termini)
0.994 sequence-only estimate (linear, free termini)
Evidence Records 4 records
Evidence 1 Activity

Activity

LC50
Hemolysis
15 µM
[Ref.18554256]Hemolysis against human erythrocytes (LC50=15 µM).

Target

human erythrocytes

Source & Reference

Hemolytik PD_Hemolysis
DRAMP4
Chem Biol Drug Des. 2008 Jul 72(1):58-64.

Other

Source Activity Label Source Definition
Hemolysis
Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 2 Activity

Activity

50% Hemolysis
Toxicity
15 µM
Hemolytic Cytotoxic
50% Hemolysis | 15 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of potent, non-toxic antimicrobial agents based upon the naturally occurring frog skin peptides, ascaphin-8 and peptide XT-7. | Chem Biol Drug Des | 2008
Evidence 3 Activity

Activity

LC50
Toxicity
15 µM
Hemolytic
Hemolytic_activity: [Ref.18554256]Hemolysis against human erythrocytes (LC50=15 µM).

Target

erythrocytes

Source & Reference

NA
DRAMP
Chem Biol Drug Des. 2008 Jul 72(1):58-64.
Evidence 4 Hemolysis

Activity

15 µM
LC50
[Ref.18554256]Hemolysis against human erythrocytes (LC50=15 µM).
Hemolysis

Target

human erythrocytes

Source & Reference

HemoPI PD_Hemolysis
Chem Biol Drug Des. 2008 Jul 72(1):58-64.
DRAMP4
PD_Hemolysis